ClinicalTrials.gg

Program

enlicitide

Also written as “Enlicitide”.

Its studies are mostly in Renal Insufficiency · Hyperlipidemias · Hepatic Insufficiency · Hypercholesterolemia, led by Merck.

Furthest: phase 3, since Jun 4, 202414 company-led studies, 3 open or runningNext primary completion: Dec 14, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck143 open or runningphase 3since Jun 4, 2024Jun 4, 2024Dec 14, 2026phase 1 · NCT07776665

Also a collaborator on its studies: celerion.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 4, 2024First study: phase 3 study in HypercholesterolemiaFirst studyNCT06450366 · 301 enrolled · United States, Argentina, Canada and more
  2. Aug 26, 2024Phase 1 study in Hepatic InsufficiencyNCT06575959 · 20 enrolled · United States
  3. Sep 12, 20242 phase 1 studies in HealthyNCT06597760, NCT06609512
  4. Oct 14, 2024Phase 1 study in Renal InsufficiencyNCT06643377 · 27 enrolled · United States
  5. Dec 2, 2024Phase 1 study in HealthyNCT06719544 · 16 enrolled · United States
  6. Mar 12, 2025Phase 1 study in HealthyNCT06880874 · 40 enrolled · United States
  7. Jun 26, 2025Phase 1 study in HealthyNCT07044479 · 60 enrolled · United States
  8. Oct 10, 2025Phase 3 study in HyperlipidemiasNCT07216482 · 996 enrolled · United States, Argentina, Australia and more
  9. Dec 10, 2025Phase 1 study in HealthyNCT07300280 · 60 enrolled · United States
  10. Mar 16, 2026Phase 1 study in HealthyNCT07481708 · 30 enrolled · United States
  11. May 22, 2026Phase 2 study in Lipoprotein(a)NCT07614984 · 750 planned · United States, Canada, Colombia and more
  12. May 27, 2026Phase 1 study in HealthyNCT07619443 · 30 enrolled · United States
  13. Aug 17, 2026Phase 1 study in HealthyNCT07776665 · 30 enrolled · United States

Ahead

  1. Dec 14, 2026Primary completion: phase 1 study in HealthyNCT07776665
  2. Oct 12, 2027Primary completion: phase 2 study in Lipoprotein(a)NCT07614984

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07776665Healthy · United States1Active, not recruitingDec 14, 202630
NCT07619443Healthy · United States1CompletedSep 5, 202630
NCT07614984Lipoprotein(a) · United States, Canada, Colombia and more2RecruitingOct 12, 2027750
NCT07481708Healthy · United States1CompletedMay 18, 202630
NCT07300280Healthy · United States1CompletedOct 14, 202660
NCT07216482Hyperlipidemias · United States, Argentina, Australia and more3Active, not recruitingAug 3, 2026996
NCT07044479Healthy · United States1CompletedAug 13, 202560
NCT06880874Healthy · United States1CompletedMay 16, 202540
NCT06719544Healthy · United States1CompletedJan 27, 202516
NCT06643377Renal Insufficiency · United States1CompletedJun 25, 202527
NCT06609512Healthy · United States1CompletedJan 13, 202520
NCT06597760Healthy · United States1CompletedNov 1, 202424
NCT06575959Hepatic Insufficiency · United States1CompletedMay 1, 202520
NCT06450366Hypercholesterolemia · United States, Argentina, Canada and more3CompletedFeb 14, 2025301

How it is read

Names in the registry

  • “Enlicitide”, 13 entries
  • “enlicitide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.